RCUS Stock Analysis Today
Updated Nov 8, 2026 · trends, key levels, insider activity and news
Is RCUS bullish or bearish today?
Daily trend: Downtrend (starting) — turns up above $31.73
SEPT signal: Accumulation · Consolidating
Research grade: B · fair value $26.80 (+140.7%)
RCUS trend by timeframe
| Daily | Downtrend (starting) |
|---|---|
| 4 hour | Symmetric Triangle |
| 1 hour | Strong Bullish |
| 15 min | Strong Bearish |
| 5 min | Strong Bullish |
Trends are calculated from price structure and update during market hours.
RCUS support and resistance levels
Resistance (above)
$19.6210 touches
$20.991 touches
$22.809 touches
Support (below)
$17.438 touches
$15.097 touches
$13.492 touches
Upside zones: $19.42 / $19.59 / $19.75
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 130-day net
—Hedge fund holders
198Latest RCUS news and filings
- AnalystBenzinga
Leerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49
Leerink Partners reiterated its Outperform rating on Arcus Biosciences and raised its price target to $49. The update reflects the analyst's view on the stock.
- AnalystBenzinga
Truist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40
Truist Securities reiterated a Buy rating on Arcus Biosciences while reducing its price target to $40. The change reflects the firm's updated view on the stock.
- AnalystFiscal.ai
Wedbush lowers Arcus Biosciences target to $45 from $49
Wedbush reduced its valuation estimate for Arcus Biosciences, now at $45 versus $49 before. The adjustment reflects the firm's revised outlook on the shares.
- AnalystBenzinga
Wedbush keeps Outperform rating on Arcus Biosciences, cuts target to $45
Wedbush reiterated an Outperform rating on Arcus Biosciences while reducing its price target to $45. The change reflects the firm's updated view on the stock.
- EarningsFiscal.ai
Arcus Biosciences posts Q3 2026 results, updates drug pipeline
The biotech company shared its quarterly financial figures for the three months ended in 2026 and gave an update on its drug development programs. No specific numbers appeared in the headline.
- EarningsBenzinga
Arcus Biosciences posts wider quarterly loss but revenue tops estimates
The company reported a per-share loss of $1.00 for its latest quarter, missing the $0.90 loss analysts expected. Revenue of $9.000 million came in above the $8.305 million estimate.
Live RCUS chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Is RCUS bullish or bearish today?
RCUS daily trend: Downtrend (starting) — turns up above $31.735. SEPT signal: Accumulation (Consolidating). Updated Nov 8, 2026.
What is RCUS's trend on each timeframe?
Daily: Downtrend (starting); 4 hour: Symmetric Triangle; 1 hour: Strong Bullish; 15 min: Strong Bearish; 5 min: Strong Bullish.
What are RCUS support and resistance levels?
Support: $17.43, $15.09, $13.49. Resistance: $19.62, $20.99, $22.80. Last price $18.28.
Are insiders buying or selling RCUS?
Insider signal: Sell. Last 30 days: 0 buys, 1 sells. 198 hedge funds hold RCUS.
What is the latest news on RCUS?
Nov 5, 2026: Leerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49 · Nov 5, 2026: Truist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40 · Nov 5, 2026: Wedbush lowers Arcus Biosciences target to $45 from $49